A soon-to-be-tested class of drug inhibitors were predicted to help a limited number of patients with B-cell lymphomas with mutations affecting the EZH2 protein. However medical researchers now report that these agents may, in fact, help a much broader cross section of lymphoma patients.
Fuente : http://feeds.sciencedaily.com/~r/sciencedaily/~3/Q...
Fuente : http://feeds.sciencedaily.com/~r/sciencedaily/~3/Q...